Bitget App
Trade smarter
MarketsTradeFuturesStocksEarnInstitutionAI & More
UBS: Resumes coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating; potential of blockbuster drug Dupixent underestimated

UBS: Resumes coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating; potential of blockbuster drug Dupixent underestimated

智通财经智通财经2026/10/15 06:46
Show original

UBS has resumed coverage of Regeneron Pharmaceuticals (REGN.US) with a "Buy" rating and a target price of $978.

Jitong Finance APP has learned that UBS has resumed coverage of Regeneron Pharmaceuticals (REGN.US), assigning a "Buy" rating with a target price of $978, which is about 30% higher than the latest closing price. The bank previously rated the stock as "Neutral".

UBS analyst Joon Lee stated that the market has not fully reflected two aspects of value: first, Regeneron's potential in developing follow-up products to its Dupixent (dupilumab); second, the prospect of an extended exclusivity period for the drug. Dupixent is a blockbuster medication co-developed by Regeneron and Sanofi (SNY.US).

Lee pointed out that next-generation Dupixent candidate drugs "may fill the gap created when patent exclusivity expires." The company may be able to extend exclusivity beyond 2031.

Among the four next-generation Dupixent candidate drugs currently under development, one may reveal data early next year and subsequently begin phase 3 trials in the second half of 2027. Lee said that the other three next-generation candidates are planned to start phase 1/2 clinical trials in early 2027, and phase 3 studies between 2027 and 2028. Lee also mentioned that patent reviews show these candidate drugs have differentiated features. For example, they can achieve "optimized target binding" in a pH-dependent manner, thereby improving target clearance and drug durability.

He expects Dupixent’s revenue to reach $16 billion by 2035, while market consensus forecasts $13 billion.

Lee added: “Dupixent’s multi-layered intellectual property protection system and Sanofi’s comments about IP protection until 2046 are certainly worth considering from a risk-adjusted perspective. Litigation involves more than 50 patents, is time-consuming and labor-intensive, and the risks associated with product launch are high, meaning competitors may bear liability for damages... These are all key factors to consider.”

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Barclays (BCS.US) bets on a merger between Tesla (TSLA.US) and SpaceX (SPCX.US) in December, but prediction markets give only a 19% probability.

Barclays analyst Levy predicts that Tesla and SpaceX may merge before December to achieve AI integration. However, data from Kalshi and Polymarket indicate that the probability of a short-term merger is very low, with the market favoring such a move after 2027.

智通财经•2026/10/15 09:07

Barclays (BCS.US) bearish on Dell (DELL.US): No inflection point in AI spending, memory costs are the main reason

Barclays has downgraded Dell from Overweight to Neutral and lowered the target price. The institution noted that corporate AI spending remains low and revenue growth is driven by memory shortages, which stands in stark contrast to Michael Dell’s optimistic outlook.

智通财经•2026/10/15 09:06